Skin Aging Clinical Trial
NCT number | NCT00856414 |
Other study ID # | MA-BTX-0806 |
Secondary ID | |
Status | Completed |
Phase | Phase 4 |
First received | |
Last updated | |
Start date | March 2009 |
Est. completion date | April 2009 |
Verified date | January 2019 |
Source | Allergan |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study evaluates the patient satisfaction and onset of effect following treatment with botulinum toxin Type A in the treatment of glabellar rhytids (frown lines)
Status | Completed |
Enrollment | 45 |
Est. completion date | April 2009 |
Est. primary completion date | April 2009 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 35 Years to 55 Years |
Eligibility |
Inclusion Criteria: - Female subjects of any race, 35-55 years of age - Moderate to severe glabellar wrinkles (lines between the eyebrows) Exclusion Criteria: - Previous botulinum toxin therapy - Subjects who are pregnant, breast-feeding, or who are of childbearing potential and not practicing a reliable method of birth control - Subjects planning a facial cosmetic procedure or visible scars - Previous cosmetic surgery to the upper face - Medical condition that may increase their risk of exposure to botulinum toxin including diagnosed Myasthenia Gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis, or any other disease that might interfere with neuromuscular function - History of facial nerve palsy - Allergy or sensitivity to any component of the study medication |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Allergan |
United States,
Beer KR, Boyd C, Patel RK, Bowen B, James SP, Brin MF. Rapid onset of response and patient-reported outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabellar lines. J Drugs Dermatol. 2011 Jan;10(1):39-44. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The First Visit Onset of Efficacy as Measured by Physician Assessment | The first visit onset of efficacy as measured by physician assessment. Onset is determined by a yes/no answer to the question "Since injecting the patient, have you noticed any effect on the appearance of the patient's frown lines (lines between the eyebrows)?" at days 2, 3, 4, 7, and 14. | 14 Days | |
Primary | The First Visit Onset of Efficacy as Measured by Subject Assessment | The first visit onset of efficacy as measured by subject assessment. Onset is determined by a yes/no answer to the question "Since being injected, have you noticed any effect on the appearance of your frown lines (lines between the eyebrows)?" at days 2, 3, 4, 7, and 14. | 14 Days | |
Secondary | Average Subject Assessment Score in Improvement of Appearance of Frown Lines | Average subject assessment score in improvement of appearance of frown lines (lines between the eyebrows) as measured by a 7-point scale (1=very much improved and 7=very much worse)on a daily basis. The average scores over the 1st diary week (1-7 days) and the 2nd diary week (8-14 days) are presented. | 14 Days | |
Secondary | Change From Baseline in Patient Satisfaction as Measured by Facial Line Outcome (FLO) Questionnaire Score | Change from baseline in patient satisfaction as measured by FLO questionnaire comprised of 11 items that assess subject's perceptions about specific aspects of their facial lines for the previous 7 days. Each question is scored on a 11-point scale (0=not at all, 5=somewhat, 10=very much) and the sums are converted to the total FLO score. The minimum total FLO score is 0 (worst) and the maximum total FLO score is 100 (best). The total FLO score was calculated at baseline and Day 14. A positive number change from baseline indicates an improvement. | Baseline, Day 14 | |
Secondary | Percentage of Patients Reporting Self-Perception of Age (SPA) | Percentage of patients reporting their SPA. SPA is measured by a questionnaire. Patients were asked to compare their facial appearance to their current age. Response options were "Looking younger", "Looking current age", and "Looking older". Results for each response are presented for Baseline and Day 14. | Baseline, Day 14 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04276753 -
A Randomized, Double-blinded, Placebo Controlled, Monocentric Study to Evaluate the Anti-ageing and Skin Brightening Benefit of the Test Product in Healthy Female Subjects
|
N/A | |
Completed |
NCT06125912 -
A Comparative Split-Face Study of the Effects of a Retinol Alternative Cream on Improving Facial Skin Aging
|
N/A | |
Completed |
NCT02580370 -
Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines
|
Phase 3 | |
Recruiting |
NCT01583478 -
Comparison of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids
|
Phase 4 | |
Completed |
NCT02003833 -
Poly-L-lactic Acid for Skin Quality
|
Phase 4 | |
Completed |
NCT01447342 -
A Study to Evaluate the Safety and Effectiveness of the Cryo-Touch II Device for the Treatment of Forehead and/or Glabellar Lines
|
Phase 2/Phase 3 | |
Completed |
NCT00974480 -
Comparison of Redermic, Rejuva-A and Combination of Both Redermic and Rejuva-A in Subjects With Signs of Aging
|
N/A | |
Completed |
NCT00986570 -
Clinical Trial to Assess Efficacy, Safety and Tolerability of Botulinum Toxin A (Xeomin®) in Treatment of Expression Wrinkles in the Upper Third of the Face
|
Phase 3 | |
Completed |
NCT00272610 -
Topical Vitamin A Versus Vehicle Cream in the Treatment of Aged Skin
|
Phase 2 | |
Recruiting |
NCT03730649 -
Effect of Topical Sulforaphane on Skin Aging and With Ultraviolet and Visible Light Exposure
|
Early Phase 1 | |
Completed |
NCT03312543 -
Evaluation of the Efficacy and Tolerance of a Light Therapy Mask on Mild to Moderate Brown Spots and Moderate to Severe Facial Wrinkles
|
N/A | |
Active, not recruiting |
NCT05349799 -
TEOSYAL RHA® 1 for Neck Lines, Perioral Lines and Smiling Lines
|
N/A | |
Completed |
NCT03677258 -
Effectiveness and Safety of Collagen Complex COLLOST in Anti-age Therapy
|
N/A | |
Withdrawn |
NCT05854628 -
The Role of Red Flavonoid in Photoaging
|
N/A | |
Completed |
NCT01981980 -
Comparison of the Effects of Carboxytherapy and Radiofrequency on Skin Rejuvenation
|
N/A | |
Not yet recruiting |
NCT00767156 -
Effects of Oral and Topical Sea Buckthorn Oil Treatments on Skin Aging
|
N/A | |
Recruiting |
NCT05813054 -
Clinical Study to Evaluate the Anti-aging Efficacy of Dermial®
|
N/A | |
Not yet recruiting |
NCT04485091 -
TCA Peel and Photobiomodulation for Hand Rejuvenation
|
Phase 2 | |
Completed |
NCT05457491 -
Novel Antiaging Regenerative Skin Care Regimen Containing Human Platelet Extract (HPE)
|
Phase 1 | |
Completed |
NCT01237977 -
Efficacy and Safety Study of Botulinum Toxin Type A to Treat Glabellar Lines
|
Phase 3 |